Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Obesity

Government told to make changes to food packaging in obesity crisis battle

People most used the traffic light system when choosing snacks

The Independent UK

People regain weight within two years of coming off obesity drugs, new study finds

People who use weight-loss drugs can rapidly regain weight after stopping treatment, according to a new study

Euronews

Thursday briefing: Why skinny jabs’ short-term fix comes with long-term concerns

In today’s newsletter: A new study shows that people don’t just regain weight after stopping GLP-1 drugs, they see other positive health markers reverse – leading to questions about long-term impacts and solutions

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Stopping weight-loss jabs leads to much faster rebound than thought – so are they still worth it?

Weight-loss injections, like Wegovy and Mounjaro, have been hailed as gamechangers. In clinical trials, people lost an average of 15%-20% of their body weight – results that seemed almost miraculous compared to traditional diet and exercise programmes.

The Conversation

Lack of support leaving people on weight loss drugs vulnerable to nutritional deficiencies, say experts

Many taking weight loss drugs could be at risk of ‘replacing one set of health problems with another’, academics warned

The Independent UK

People on fat loss jabs ‘put weight back on faster than traditional dieters’

The vast majority of people taking Wegovy and Mounjaro pay privately owing to restrictions on who can access the medicines via the NHS.

Evening Standard

How eggs can help you come off Wegovy – cracking the problem of weight-regain

For millions of people, weight-loss injections such as Wegovy and Mounjaro have felt like a breakthrough that finally makes eating less feel easier. In a few short years, these so-called GLP-1 drugs have reshaped how obesity is treated and how people think about appetite and willpower. But their success raises…

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Experts warn ‘loophole’ means junk food advert ban doesn’t go far enough

A loophole in the ban means companies can still advertise brand names, which experts argue leaves children no better protected

The Independent UK

Tuesday briefing: Will a ban on advertising junk food help to tackle obesity in the UK?

In today’s newsletter: As new rules ban TV and online ads for high-fat, salt and sugar products, the curbing of junk food marketing has found cross-party support

The Guardian - UK

The Guardian view on the junk food advertising ban: shaping tastes is a job for government

Editorial: Weight-loss drugs cannot solve the problem of poor diet. Ministers are right to demand healthier food and promotions

The Guardian - UK

Forget BMI – this is the real way to predict how healthy you are, experts say

Waist-to-height ratio ‘outperforms’ BMI in identification of serious health risks, analysis of over 120,000 people suggests

The Independent UK

Ban on TV junk food advertising before 9pm comes into force in UK

Watchdog will also monitor online ban for high fat and sugar products as part of wider effort to tackle childhood obesity

The Guardian - UK

UK ban on adverts for ‘unhealthy’ food comes into effect in bid to tackle obesity

The government estimates the advertising ban will prevent around 20,000 cases of childhood obesity

The Independent UK

New crackdown on ads for ‘less healthy food’ to come into full effect

The ban applies to products that fall within 13 categories considered to play the most significant role in childhood obesity

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Ban on adverts for ‘less healthy food’ set to come into full effect

They will not be allowed to appear on television between 5.30am and 9pm, or online at any time.

The Guardian - UK

The WHO learned to love ‘anti-obesity’ jabs in 2025. I don’t fully agree, but I get it

While GLP-1 drugs promise an easy fix, our bodies still need what they have always needed: healthy food and regular exercise, says chair of global public health at the University of Edinburgh, Prof Devi Sridhar

Barchart

This Small But Mighty Stock Could Surprise Investors in 2026

This under-the-radar biotech stock is setting up for a big 2026.

Barchart

As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

Sleds over screens: Why it’s time to limit your children’s screen time this Christmas

Heavy use of phones, tablets and gaming consoles has been linked to anxiety, depression, poor attention and even obesity.

Euronews

US approves pill version of blockbuster weight-loss drug Wegovy

Availability of oral pills to treat obesity could expand the booming market for obesity treatments by broadening access and reducing costs, experts said.

The Independent UK

FDA approves Wegovy weight-loss pill in first green-lit alternative to injectable GLP-1 drugs

U.S. regulators have approved a pill version of the weight-loss drug Wegovy, a boon for drugmaker Novo Nordisk

The Guardian - UK

India’s doctors sound alarm over boom in availability of weight loss jabs

Country is facing epidemic of diabetes and obesity, but experts say widespread and unregulated use of weight loss drugs could put patients at risk

MarketBeat

Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

The Independent UK

A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic knee pain after 68 weeks

International Business Times UK

Eli Lilly CEO David Ricks Unveils $6B Alabama Plant to Produce New Obesity Pill

Eli Lilly CEO David Ricks has announced a new $6 billion manufacturing plant in Alabama dedicated to producing the company's next-generation obesity pill. The move signals Lilly's aggressive expansion as global demand for weight-loss drugs soars.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the University of Edinburgh

243 stories

the University of Cambridge

196 stories

Novo

166 stories

the University of Oxford

155 stories

NVO

136 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.